4.7 Article

Spatial Network Mapping of Pulmonary Multidrug-Resistant Tuberculosis Cavities Using RNA Sequencing

出版社

AMER THORACIC SOC
DOI: 10.1164/rccm.201807-1361OC

关键词

transcriptomics; pulmonary tuberculosis; in silico analysis; TB cavitation

资金

  1. Baylor Research Institute
  2. NIH [DP2 OD001886, R01AI079497, R56 AI111985]
  3. South African MRC
  4. European Developing Clinical Trials Partnership
  5. National Research Foundation
  6. Oppenheimer Foundation
  7. Wellcome Trust [207511/Z/17/Z, WT101766/Z/13/Z]
  8. Medical Research Council [MR/M003833/1]
  9. NIHR Biomedical Research Funding
  10. MRC [MR/M003833/1] Funding Source: UKRI

向作者/读者索取更多资源

Rationale: There is poor understanding about protective immunity and the pathogenesis of cavitation in patients with tuberculosis. Objectives: To map pathophysiological pathways at anatomically distinct positions within the human tuberculosis cavity. Methods: Biopsies were obtained from eight predetermined locations within lung cavities of patients with multidrug-resistant tuberculosis undergoing therapeutic surgical resection (n = 14) and healthy lung tissue from control subjects without tuberculosis (n = 10). RNA sequencing, immunohistochemistry, and bacterial load determination were performed at each cavity position. Differentially expressed genes were normalized to control subjects without tuberculosis, and ontologically mapped to identify a spatially compartmentalized pathophysiological map of the cavity. In silico perturbation using a novel distance-dependent dynamical sink model was used to investigate interactions between immune networks and bacterial burden, and to integrate these identified pathways. Measurements and Main Results: The median (range) lung cavity volume on positron emission tomography/computed tomography scans was 50 cm(3) (15-389 cm(3)). RNA sequence reads (31% splice variants) mapped to 19,049 annotated human genes. Multiple proinflammatory pathways were upregulated in the cavity wall, whereas a downregulation sink in the central caseum-fluid interface characterized 53% of pathways including neuroendocrine signaling, calcium signaling, triggering receptor expressed on myeloid cells-1, reactive oxygen and nitrogen species production, retinoic acid-mediated apoptosis, and RIG-I-like receptor signaling. The mathematical model demonstrated that neuroendocrine, protein kinase C-theta, and triggering receptor expressed on myeloid cells-1 pathways, and macrophage and neutrophil numbers, had the highest correlation with bacterial burden (r > 0.6), whereas T-helper effector systems did not. Conclusions: These data provide novel insights into host immunity to Mycobacterium tuberculosis-related cavitation. The pathways defined may serve as useful targets for the design of host-directed therapies, and transmission prevention interventions.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Infectious Diseases

Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trial

Shabir A. Madhi, Gaurav Kwatra, Simone Richardson, Anthonet L. Koen, Vicky Baillie, Clare L. Cutland, Lee Fairlie, Sherman D. Padayachee, Keertan Dheda, Shaun L. Barnabas, Qasim Ebrahim Bhorat, Carmen Briner, Khatija Ahmed, Parvinder K. Aley, Sutika Bhikha, A. E. Bhorat, Aliasgar Esmail, Elizea Horne, Haajira Kaldine, Christian K. Mukendi, Vimbai Sharon Madzorera, Nelia P. Manamela, Mduduzi Masilela, S. Tandile Hermanus, Thopisang Motlou, Nonkululeko Mzindle, Suzette Oelofse, Faeezah Patel, Sarah Rhead, Lindie Rossouw, Carol Taoushanis, Samuel van Eck, Teresa Lambe, Sarah C. Gilbert, Andrew J. Pollard, Penny L. Moore, Alane Izu

Summary: A study in Africa found that SARS-CoV-2 infection before vaccination with the AZD1222 vaccine can enhance antibody responses for up to 180 days. This has important implications for the COVID-19 vaccine rollout in Africa.

LANCET INFECTIOUS DISEASES (2023)

Article Infectious Diseases

The impact of enteral feeding and therapeutic monitoring of rifampicin with dose escalation in critically ill patients with tuberculosis

Rubeshan Perumal, Kogieleum Naidoo, Anushka Naidoo, Marothi P. Letsoalo, Aliasgar Esmail, Ivan Joubert, Paolo Denti, Lubbe Wiesner, Nesri Padayatchi, Gary Maartens, Keertan Dheda

Summary: This study investigates the pharmacokinetics of rifampicin and the impact of continuous enteral feeding on drug absorption in critically ill patients with tuberculosis. Therapeutic drug monitoring (TDM) with dose escalation is found to be an effective strategy to achieve target drug exposure in these patients.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2023)

Article Immunology

Isoniazid pharmacokinetics/pharmacodynamics as monotherapy and in combination regimen in the hollow fiber system model of Mycobacterium kansasii

Gunavanthi D. Boorgula, Sanjay Singh, Prem Shankar, Tawanda Gumbo, Scott K. Heysell, Shashikant Srivastava

Summary: This study found that the recommended dose of isoniazid for the treatment of Mycobacterium kansasii pulmonary disease may be insufficient. Higher doses of isoniazid in combination with other drugs showed better clinical efficacy in an experimental model.

TUBERCULOSIS (2023)

Article Ophthalmology

Intraocular Microbiome in Diabetes and Diabetic Retinopathy: A Pilot Study

Taraprasad Das, Shalem Raj Padakandla, Sisinthy Shivaji, Rajagopalaboopathi Jayasudha, Brijesh Takkar

Summary: This study compared the microbiome in the aqueous humour and gut of people with diabetes mellitus (DM) with and without diabetic retinopathy (DR). It was found that there are differences in the microbiome of the eye and gut regardless of disease or health. The intraocular microbiome showed more distinct features compared to the gut, but further confirmation is needed with larger studies.

OPHTHALMOLOGY AND THERAPY (2023)

Article Medicine, General & Internal

Outcomes of patients undergoing lung resection for drug-resistant TB and the prognostic significance of pre-operative positron emission tomography/computed tomography (PET/CT) in predicting treatment failure

Gregory L. Calligaro, Nevadna Singh, Timothy C. Pennel, Rachelle Steyn, Anita Brink, Aliasgar Esmail, Lynelle Mottay, Suzette Oelofse, Barbara L. Mastrapa, Wisdom Basera, Kathryn Manning, Chima Ofoegbu, Anthony Linegar, Keertan Dheda

Summary: This study investigated the treatment outcomes of drug-resistant tuberculosis patients who underwent surgery, and found that surgical intervention combined with chemotherapy led to better treatment success. However, pre-operative PET-CT did not predict treatment outcomes.

ECLINICALMEDICINE (2023)

Article Infectious Diseases

Hollow-fibre system model of tuberculosis reproducibility and performance specifications for best practice in drug and combination therapy development

Tawanda Gumbo, Shashikant Srivastava, Devyani Deshpande, Jotam G. Pasipanodya, Alexander Berg, Klaus Romero, David Hermann, Debra Hanna

Summary: This study evaluated the effect of different drug combinations on Mycobacterium tuberculosis using the hollow-fibre system model (HFS-TB). The results showed that HFS-TB is a highly tractable tool for choosing combination regimens with little variability between teams, and between replicates.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2023)

Review Infectious Diseases

Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement

Jose Dominguez, Martin J. Boeree, Emmanuelle Cambau, Dumitru Chesov, Francesca Conradie, Vivian Cox, Keertan Dheda, Andrii Dudnyk, Maha R. Farhat, Sebastien Gagneux, Martin P. Grobusch, Matthias Groeschel, Lorenzo Guglielmetti, Irina Kontsevaya, Berit Lange, Frank van Leth, Christian Lienhardt, Anna M. Mandalakas, Florian P. Maurer, Matthias Merker, Paolo Miotto, Barbara Molina-Moya, Florence Morel, Stefan Niemann, Nicolas Veziris, Andrew Whitelaw, Charles R. Horsburgh Jr, Christoph Lange

Summary: Drug-resistant tuberculosis is a global concern and molecular methods provide rapid information on mutations associated with anti-tuberculosis drug resistance. This consensus document, developed by TBnet and RESIST-TB networks, establishes reporting standards for the clinical use of molecular drug susceptibility testing. The panel identified studies linking M tuberculosis mutations with treatment outcomes, and highlights the importance of implementing molecular testing for drug resistance prediction.

LANCET INFECTIOUS DISEASES (2023)

Article Biochemistry & Molecular Biology

Recent Changes in Suicide Rates, by Race and Ethnicity and Age Group - United States, 2021

Aliasgar Esmail, Philippa Randall, Suzette Oelofse, Michele Tomasicchio, Anil Pooran, Richard Meldau, Edson Makambwa, Lynelle Mottay, Shameem Jaumdally, Gregory Calligaro, Stuart Meier, Marianna de Kock, Tawanda Gumbo, Robin Mark Warren, Keertan Dheda

Summary: Two in every five patients with active tuberculosis (TB) remain undiagnosed or unreported, highlighting the need for urgent implementation of community-based active case-finding strategies. Through an open-label, randomized controlled trial in periurban informal settlements of Cape Town, South Africa, it was found that portable, battery-operated molecular diagnostic tools can shorten time-to-treatment initiation compared to conventional POC smear microscopy, potentially curtailing transmission.

NATURE MEDICINE (2023)

Article Multidisciplinary Sciences

Variation in missed doses and reasons for discontinuation of anti-tuberculosis drugs during hospital treatment for drug-resistant tuberculosis in South Africa

Elize Pietersen, Kim Anderson, Helen Cox, Keertan Dheda, Aihua Bian, Bryan E. Shepherd, Timothy R. Sterling, Robin M. Warren, Yuri F. van der Heijden

Summary: This study found that incomplete treatment with certain anti-TB drugs, such as second-line injectables and para-aminosalicylic acid (PAS), was more common than with other drugs in the treatment of drug-resistant tuberculosis. The reasons for discontinuation varied, with adverse events being the main cause for discontinuation of second-line injectables and patient refusal for discontinuation of PAS.

PLOS ONE (2023)

Article Immunology

Efficacy of primary series AZD1222 (ChAdOx1 nCoV-19) vaccination against SARS-CoV-2 variants of concern: Final analysis of a randomized, placebo-controlled, phase 1b/2 study in South African adults (COV005)

Anthonet L. Koen, Alane Izu, Vicky Baillie, Gaurav Kwatra, Clare L. Cutland, Lee Fairlie, Sherman D. Padayachee, Keertan Dheda, Shaun L. Barnabas, Qasim Ebrahim Bhorat, Carmen Briner, Khatija Ahmed, Sutika Bhikha, Jinal N. Bhiman, Jeanine du Plessis, Aliasgar Esmail, Elizea Horne, Shi-Hsia Hwa, Aylin Oommen-Jose, Teresa Lambe, Matt Laubscher, Mookho Malahleha, Gabriella Benade, Shakeel McKenzie, Suzette Oelofse, Faeezah Patel, Sureshnee Pillay, Sarah Rhead, Hylton Rodel, Carol Taoushanis, Houriiyah Tegally, Asha Thombrayil, Tonya L. Villafana, Sarah Gilbert, Andrew J. Pollard, Shabir A. Madhi

Summary: The final analysis of the COV005 study in South African adults showed that the efficacy of the AZD1222 vaccine varied against different SARS-CoV-2 variants. The vaccine had high efficacy against the wild type virus, but lower efficacy against the Beta and Delta variants. Safety was consistent with previous findings.

VACCINE (2023)

Article Biology

Insights into cargo sorting by SNX32 and its role in neurite outgrowth

Jini Sugatha, Amulya Priya, Prateek Raj, Ebsy Jaimon, Uma Swaminathan, Anju Jose, Thomas John Pucadyil, Sunando Datta, Felix Campelo

Summary: SNX32 interacts with SNX4 via its BAR domain and with TfR, CIMPR, and BSG through its PX domain, regulating cargo sorting and trafficking processes. Silencing of SNX32 leads to defects in intracellular trafficking and neuronal differentiation, suggesting its crucial role in maintaining neuroglial coordination.
Article Infectious Diseases

Omadacycline pharmacokinetics/pharmacodynamics in the hollow fiber model and clinical validation of efficacy to treat pulmonary Mycobacterium abscessus disease

Sanjay Singh, Jann-Yuan Wang, Scott K. Heysell, Pamela J. McShane, Carly Wadle, Prem Shankar, Hung-Ling Huang, Jotam Pasipanodya, Gunavanthi D. Boorgula, Julie V. Philley, Tawanda Gumbo, Shashikant Srivastava

Summary: Based on experimental and retrospective clinical studies, it was found that a daily dose of 300 mg of omadacycline achieved good efficacy and had minimal toxicity in the treatment of pulmonary Mab disease. This finding provides a scientific basis for the clinical use of omadacycline.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2023)

Letter Immunology

Comment on Long-term Safety and Tolerability of Omadacycline for the Treatment of Mycobacterium abscessus Infections

Shashikant Srivastava, Tawanda Gumbo

OPEN FORUM INFECTIOUS DISEASES (2023)

Article Infectious Diseases

Meropenem-vaborbactam restoration of first-line drug efficacy and comparison of meropenem-vaborbactam-moxifloxacin versus BPaL MDR-TB regimen

Sanjay Singh, Tawanda Gumbo, Jan-Willem Alffenaar, Gunavanthi D. Boorgula, Prem Shankar, Tania A. Thomas, Keertan Dheda, Lesibana Malinga, Prithvi Raj, Santosh Aryal, Shashikant Srivastava

Summary: By testing and studying, it was found that the combination of meropenem with beta-lactamase inhibitors (BLIs) could potentially be an effective treatment regimen for multidrug-resistant tuberculosis (MDR-TB). The meropenem-vaborbactam-moxifloxacin backbone regimen has implications for creating a new effective MDR-TB regimen.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2023)

暂无数据